APRIL 16-18, 2019

BOSTON, MA USA

 

Nutrition Track Agenda Announced for 4th Annual Translational Microbiome Conference

Nutrition track focuses on development of nutrition-based treatments and regulatory challenges related to medical food

MINNEAPOLIS, March 29, 2018– Arrowhead Publishers released a parallel nutrition track agenda for the 4th Annual Translational Microbiome Conference, scheduled April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies generating microbiome-based medical solutions. Sponsored by Nestlé Health Science, the nutrition track focuses on issues and learnings around development of medical food, with specific examples of innovative nutritional treatments for IBD and obesity. The focused sessions will cover current regulatory criteria for medical food, as well as common regulatory challenges faced by companies innovating in nutrition science.
“Nutrition science is advancing at such a rapid rate, and regulation is complex and dynamic,” said John Waslif, Managing Director of Arrowhead Publishers. “We designed the nutrition track at our 4th Annual Translational Microbiome Conference as a forum for thought leaders to share best practices and insights, because collaboration in this environment can help speed development and clear hurdles.”
A growing body of research showcases the role nutritional solutions can play in prevention and treatment of many common issues, and nutrition track sessions are developed to provide translational insight to other companies navigating that path.
Nutrition track sessions include:

Eating for Two: Developing Nutritional Interventions and Naturally Derived Products that Consider Host and Microbial Requirements for Improved Human Health
Paul Giannasca, Ph.D., Global Scientific Lead, GI Health, Nestlé Health Science
The design of new nutritional measures and therapies will be advanced through an integrated approach incorporating knowledge of host nutrition, GI biology, our bacterial symbionts and the many intersecting metabolic pathways. The presentation will summarize ongoing efforts to develop nutritional interventions for IBD, the use of traditional Chinese botanicals to develop drugs for GI health and the mining of bacterial culture collections for beneficial strains.

Diet, the Gut Microbiome, and its Metabolome in Inflammatory Bowel Disease: Therapeutic Opportunities
Elliot Friedman, Ph.D., Senior Research Investigator, Division of Gastroenterology, Technical Director, Microbial Culture & Metabolomics Core, PennCHOP Microbiome Program, Perelman School of Medicine, University of Pennsylvania
The environment of the gut, namely the microbiota and diet, plays an important role in the pathogenesis of the inflammatory bowel diseases (IBD) that afflict approximately 3 million patients in the U.S. alone. Characterization of the impact of diet on both the composition of the gut microbiota as well as the metabolites that are produced might lead to the discovery of alternative strategies to treat IBD by engineering the environment of the gut. Using defined formula diets as a therapeutic probe, we describe several human subject studies that are designed to help determine better diets for patients with IBD that can be used to treat and/or prevent the recurrence of active disease.


Nutritional Approaches that impact the microbiome: Hype, Hope, and Regulatory Realities of Medical Foods
Tim Morck, Ph.D., President, Spectrum Nutrition
When research shows an impact of a product on the microbiome, with positive outcomes on certain markers of health or disease, what regulatory category does it fall under for commercialization, and what claims are permissible? This presentation will explain current regulatory criteria for medical food, and share encouraging steps being taken to address the challenges regulators face to keep pace with rapidly advancing nutritional science.


Panel Discussion: Microbiome Products as Medical Foods: Is There a Nutritional Requirement for Bacteria?
Moderated by Bernadette Janas, Ph.D., Global Medical Affairs Lead, Nestlé Health Science
Panelists:
David Beno, Ph.D., Chief Scientific Officer, Xeno Biosciences
Colleen Cutcliffe, Ph.D., Chief Executive Officer, Whole Biome
Tim Morck, Ph.D., President, Spectrum Nutrition
This panel session will explore questions such as these:
- Is the data sufficient to establish an "ideal" microbiome composition to support health, that might permit supplemental bacteria to be considered similar to an "essential nutrient" to correct an imbalance associated with a disease?
- Is lack of enforcement by the FDA toward companies marketing supplements as medical foods in the space indicative of their stance?
- Does the FDA have the resources to address this issue and how will companies in the space be able to successfully elevate the priority of this issue to a level where the FDA commits to take action to clarify this area?
- How should companies conduct a risk/benefit analysis when considering launching a new product in an uncertain regulatory space?


Pharmacological Mimicry of Gastric Bypass Microbiome to Treat Obesity
David Beno, Ph.D., Chief Scientific Officer, Xeno Biosciences
Xeno Biosciences is leveraging nascent bariatric surgery/microbiome science to develop XEN-101. We have proposed the "air hypothesis" as a mechanism to explain the profound weight loss and the associated microbiome shifts observed after gastric bypass surgery. We created XEN-101, a first-in-class, oral anti-obesity medicine. XEN-101 has preclinical and initial clinical pilot efficacy data, demonstrating substantial weight loss and corresponding shifts in the gut microbiome. Xeno is currently in early development preparing for Phase I studies.


View the full agenda for the 4th Annual Translational Microbiome Conference at www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via www.microbiomeconference.com/sponsor-exhibit.
# # #
Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.


If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Consumer Track Agenda Announced for 4th Annaul Translational Microbiome Conference

Consumer track focuses on challenges and progress insights for companies creating microbiome-based consumer products and services

MINNEAPOLIS, March 6, 2018– Arrowhead Publishers released a parallel consumer track agenda for the 4th Annual Translational Microbiome Conference, April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies innovating microbiome-based medical solutions. The consumer track focuses on issues and learnings around direct-to-consumer product and service development, with an eye toward helping companies successfully (and efficiently) navigate from research and product innovation through regulation, commercialization and marketing.

“Microbiome research is delivering medical advancements across oncology, dermatology, inflammatory disorders, mental health and many related fields,” said John Waslif, Managing Director of Arrowhead Publishers. “The consumer track at our 4th Annual Translational Microbiome Conference provides a forum for companies to share best practices and process solutions. People want to take control of their health with access to the same science that’s making headlines in leading hospitals and medical labs, and we want to help speed the path to commercialization.”
As recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, scientists are discovering specific variables within the microbiome can profoundly impact a variety of conditions and diseases. To support exploration of translational consumer applications, consumer track presentations and discussion topics are broadly applicable, spanning multiple disease states and addressing issues common to companies in this space.


Consumer track sessions include:
Probiotic Hygiene and Care Response
Robin Temmerman, Ph.D., Chief Executive Officer, Chrisal, N.V.
Resistance of microbes to antibiotics and disinfectants is growing quickly, and allergies to chemical ingredients in cleaning and personal care products are on the rise. Rapid evolution in microbiological research has led to promising new probiotic hygiene technologies in the form of cleaning and personal care applications. For the past 15 years, Chrisal has invested to develop product solutions to widespread hygiene problems like biofilm, smell and infections. Dr. Temmerman will discuss the technology, mechanisms and benefits of probiotic hygiene and care.

Probiotic Home: The Future of Clean
John Howell, Industry Technology Specialist HHC, Novozymes
Consumers are increasingly aware of the microbiota surrounding them, and its integral role in their healthy lifestyle. They may not yet think of microbiota as a solution to what they spill on the floor. Yet, microorganisms, or probiotics, are nature’s oldest and most reliable cleaning crew. They work overtime to break down organics, for a deeper and longer-lasting “probiotic clean” than conventional chemicals. While the technology has long been used industrially, this concept has just recently started to resonate with consumers for application in their home environment. Mr. Howell will share several industrial and domestic cleaning scenarios in which microorganism-containing products are currently used, and he’ll predict future consumer cleaning habits and products that will selectively reinforce the microbiome of the home.

Panel Session: The Future of Probiotic Hygiene
Moderated by Joe Rubino, R&D Director for Reckitt Benckiser, panelists will include Matt Franken, Chief Executive Officer of Aunt Fannies; Robin Temmerman, Ph.D., Chief Executive Officer of Chrisal N.V. and other industry experts.

Early Life Microbiome: Connections between Nutritional Composition, Gastrointestinal Tract and the Brain
Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Mead Johnson Nutrition (RB)
Optimal development of the microbiome is an emerging health benefit that’s likely to grow in consumer awareness and demand over time. Intestinal microbiota plays a role in metabolic, nutritional, physiological and immunological processes in the human body, and nutrition can affect gut microbiota colonization. Our research demonstrates that functional properties of early nutrition could benefit the microbiome and health. For instance, our studies have shown that early life diet with milk fat globule membrane and prebiotics promote immune, gut, and brain development and function.

Using Live Bacteria for Topical Skin Application: Regulatory Issues
Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
A growing body of data supports the importance of the skin microbiome in its role as a protective barrier against external influence. Products with live beneficial bacteria, or live biotherapeutic products (LBP’s), present the potential to improve symptoms of a multitude of skin disorders. Yet, safety of probiotic strains is of critical importance during the in vitro screening phase. By building up the safety documentation and quality controls in the production of products, Yun Probiotherapy was able to overcome EU regulatory issues and begin marketing their LBP line to consumers.

“Research in the microbiome presents tremendous potential to provide more effective treatments, cures, therapies and supplements,” said Waslif. “As investment opportunities are growing in this area, many companies are rapidly pursuing potential translational solutions. Therefore, sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings.”

View the full agenda for the 4th Annual Translational Microbiome Conference at www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via www.microbiomeconference.com/sponsor-exhibit.

If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Growing Roster of Speakers, Spanning Research and Industry, Announced for 4th Annual Translational Microbiome Conference

Conference topics will feature speakers and panels on animal models, bioinformatics challenges, intellectual property management, investment deals and approaches, pharma deals in the microbiome space, and the need for standards.

MINNEAPOLIS, November 28, 2017– Arrowhead Publishers unveils a growing roster of speakers for its 4th Annual Translational Microbiome Conference, to take place April 18-20 at Boston Marriott Long Wharf. The conference is designed to connect scientists at the forefront of microbiome research with pioneering companies investing to apply microbiome-based findings to innovate medical solutions. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health, and improved outcomes.

“The topics and speakers for this year’s conference offer real education, insights and benefits our attendees can apply within their own organizations,” said John Waslif, Managing Director of Arrowhead Publishers and Conferences.

Speakers already confirmed for the conference include:
Peter Christey, Ph.D.
Co-Founder and Chief Executive Officer, General Automation Lab Technologies (GALT)
GALT’s innovative high-throughput microbiology platform can isolate multiple species from complex samples, such as soil and stool, allowing researchers to rapidly screen whole populations or engineered libraries. Dr. Christey is leveraging GALT tools to revolutionize how microbial studies are conducted, opening previously unreachable territories for scientists to explore.

Olga Danilchanka, Ph.D.
Microbiome Lead, Exploratory Science Center, Merck
Dr. Danilchanka serves as Microbiome Lead for Merck’s Exploratory Science Center, which focuses on the earliest stages of discovery research to better understand the underlying biology of human disease. Dr. Danilchanka’s team explores the most promising areas of emerging disease biology, including the role of the microbiome in disease, and works to gain new insights to inform Merck’s ongoing drug discovery.

Pinaki Panigrahi, M.D., Ph.D.
Professor, Department of Epidemiology and Pediatrics; Director of Center for Global Health and Development, University of Nebraska Medical Center, College of Public Health
An elected fellow of the Infectious Diseases Society of America, Dr. Panigrahi has studied neonatal and child health issues in developed nations and in the developing world. His expertise spans necrotizing enterocolitis, neonatal infections, diarrhea, malaria, birth asphyxia, prematurity, stillbirths and nutrition.

Mark Smith, Ph.D.,
Chief Executive Officer, Finch Therapeutics
Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse-engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients.

Paul Giannasca, Ph.D.
Global Scientific Lead, GI Health, Nestle Health Science
Dr. Giannasca identifies and manages new nutritional and technological platforms relevant for the Gastrointestinal Health strategy for Nestle Health Science. Dr. Giannasca holds multiple U.S. patents covering active and passive immunization against Clostridium difficile disease and has published more than 25 papers in the areas of infectious diseases, vaccine development, active and passive immunization and vaccine-induced protection.

Other notable speakers participating in the 2018 conference include:
* David Kyle, Ph.D., Chief Scientific Officer, Evolve Biosystems
* Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
* Veronika Oudova, Chief Executive Officer, S Biomedic
* Travis Whitfill, Co-Founder and Chief Science Officer, Azitra
* Jennifer A. Wargo, M.D., Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

New additions to the conference this year are topic-focused tracks for nutrition and for skin. A parallel consumer track will again be offered. Each track will be closely focused on key issues in its specific industry and the challenges common to companies trying to enter the microbiome space in that area.

Keynote address for the conference will be delivered by Emeran Mayer, M.D., Ph.D.
Director, UCLA Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress; Professor, Medicine; Professor, Psychiatry and Biobehavioral Sciences; Professor, Digestive Diseases/Gastroenterology; Co-Director, CURE: Digestive Diseases Research Center; Professor, Physiology, UCLA David Geffen School of Medicine
Dr. Mayer has a career-long interest in clinical and research aspects of brain-body interactions, with a focus on brain-gut interactions in health and disease. A widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis.

Further information about the 4th Annual Translational Microbiome Conference can be found at www.microbiomeconference.com.

Press Releases

Expert Panel Discussions to be Highlight of Agenda at the 3rd Annual Translational Microbiome Conference

Minneapolis, MN – February 15, 2017 – Arrowhead Publishers is pleased to announce that a variety of expert panel discussions have been announced for its upcoming 3rd Annual Translational Microbiome Conference. This event, which will take place April 11-13, 2017 in Boston, MA, will unite presenters and attendees from academia, industry, and the government to provide a multi-stakeholder perspective on the latest trends and developments in the microbiome space. For more information, visit: http://www.microbiomeconference.com.

The CEO of CosmosID Inc. Manoj Dadlani will lead the panel on bioinformatics tools for clinical applications in metagenomics, as well as challenges to overcome in the complex clinical and regulatory environments. Panelists will also discuss the dire need for robust bioinformatics tools that can address the complex clinical and regulatory environments.

Co-founder and CEO of Whole Biome, Dr. Colleen Cultcliffe, will be leading a panel discussion on the microbiome and its growing presence in the media. As new therapeutics are being developed, the microbiome industry must find ways to overcome the hype and unrealistic timelines that can be expected by the general public.

Mohan S. Iyer, CBO at Second Genome, will be moderating the panel on pharma companies working in the microbiome industry. He and the panelists will discuss the latest partnerships between the microbiome industry and pharma, and the deals outlook for 2017.

The “Strategies and Risks for Developing Comprehensive Patent and Licensing Strategies” panel will be led by Greg Sieczkiewicz, Managing Director at MPM Capital. This panel will analyze the various challenges and opportunities that organizations will experience when developing a patent portfolio in the microbiome therapeutics industry. They will also discuss what is necessary from a licensing perspective in order to create a successful pharma-biotech relationship.

Director of Research and Development of Reckitt Benckiser, Joe Rubino, will moderate the panel discussion “Time to Put the Hygiene Hypothesis to Rest?”

JP Benya, Vice President Commercial of Assembly Biosciences will lead the panel discussion on commercial challenges and opportunities in the microbiome-based therapeutics industry. By focusing on critical factors to consider when launching a MBT including regulatory considerations, customer expectations, and messaging implications, this panel will provide expert insight into the future of microbiome-based therapeutics.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metagenomics Expert Rita Colwell to Deliver Keynote Address at Arrowhead’s 3rd Annual Translational Microbiome Conference

January 5, 2017 – Minneapolis, MN – The second keynote presentation at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will be given by Dr. Rita Colwell, Distinguished Professor at Johns Hopkins Bloomberg School of Public Health and founder of CosmosID. Her presentation will provide attendees with an overview of the application of metagenomics in improving knowledge of human biology, disease, and the environment. The conference will be taking place April 11-13, 2017 in Boston, MA. For more information, visit: http://www.microbiomeconference.com.

In an era of climate change, high-throughput sequencing and high-resolution bioinformatics are becoming increasingly powerful in microbiome studies, as well as the clinical management of infectious disease and environment. Dr. Colwell will provide several examples of using metagenomics in a clinical setting, including diarrheal disease, waterborne infections, and wastewater reuse.

Founded in 2008 by Dr. Colwell, CosmosID strives to make the world a healthier and safer place by delivering high-resolution bioinformatics for personalized monitoring of environmental bio threat agents in an accurate and cost-effective manner. For more information, visit: http://www.cosmosid.com.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Thought Leader in Microbiome Research Jack Gilbert to Present at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference

2 December 2016 – Minneapolis, MN – Jack Gilbert, the faculty director of The Microbiome Center and professor at the University of Chicago, has just been announced as the keynote speaker at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. This conference will once again unite top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics and therapeutics. This conference will be taking place April 11-13, 2017 in Boston, MA. For more information on the conference, visit: http://www.microbiomeconference.com.

As the human microbiome is quickly demonstrating huge roles in the human ecosystem, scientists are discovering that changes in the microbiome have a huge impact on a variety of conditions and diseases. Dr. Gilbert will discuss the latest evidence of these mechanisms of interaction, and how we have started to disturb the delicate balance of immune-microbe equilibrium, thus impacting the development and function of our immune systems. By applying new strategies to identify how the microbial ecosystem correlates with diseases and treatment efficacy through Microbiome-Wide Association Studies (MWAS), microbiome studies are providing a new framework for facilitating patient care.

With an increasing awareness that many of our modern diseases are “lifestyle” related and more than 50% of current medications are ineffective for the people taking them, research in the microbiome presents a potential opportunity to provide more effective treatments, cures, therapies and supplements. Reflective of this trend is the fact that investment opportunities are growing in this area and many companies are rapidly moving towards potential translational work. 

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Arrowhead Announces the Preliminary Speaker Faculty for 3rd Annual Translational Microbiome Conference

November 16 2016 – Minneapolis, MN – Arrowhead Publishers has announced the preliminary speaking faculty for the 3rd Annual Translational Microbiome Conference. This conference, taking place April 11-13, 2017 in Boston, MA, will once again bring together the top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.

This year’s conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome industry will have to recognize and navigate in order to successfully commercialize their products. For more information on the conference, visit: http://www.microbiomeconference.com.

Speakers Include:

  • James Arbogast, Ph.D., VP of Hygiene Sciences and Public Health Advancements, GOJO Industries
  • JP Benya, VP Commercial, Assembly Biosciences
  • Carrie Brodmerkel, Ph.D., Senior Director, Systems Pharmacology & Biomarkers, Janssen R&D
  • Martha Carlin, Chief Executive Revolutionary, The BioCollective
  • Rodolphe Clerval, Chief Business Officer, Enterome
  • Rita Colwell, Ph.D., Distinguished Professor, Univ. of Maryland at College Park, Johns Hopkins Univ. Bloomberg School of Public Health, President, CosmosID, Inc., Senior Advisor, Canon U.S. Life Sciences, Inc.
  • Colleen Cutcliffe, Ph.D., Co-Founder and CEO, Whole Biome
  • Manoj Dadlani, Chief Executive Officer, CosmosID
  • Xavier Duportet, Chief Executive Officer, Eligo Biosciences
  • Jack Gilbert, Ph.D., Faculty Director, The Microbiome Center, Professor, Department of Surgery, The University of Chicago, Senior Scientist (Adjunct), The Marine Biological Laboratory, Group Leader in Microbial Ecology, Argonne National Laboratory
  • Wa’el Hashad, Executive VP and CCO, Seres Therapeutics
  • Mohan Iyer, Chief Business Officer, Second Genome
  • Lee Jones, Founder, President and CEO, Rebiotix
  • Colleen Kelly, MD, FACG, Gastroenterologist, Center for Women’s Gastrointestinal Medicine, Women’s Medicine Collaborative
  • Arpita Maiti, Ph.D., Director, External R&D Innnovation, Inflammation & Immunology, Pfizer
  • KT Moortgat, Ph.D., Chief Executive Officer, Osel
  • Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences
  • Jack Oswald, Co-Founder, CTO and CEO, IsoThrive
  • Jackie Papkoff, Ph.D., SVP Research, Evelo Biosciences
  • Greg Sieczkiewicz, JD, Ph.D., Managing Director, Chief IP Counsel, MPM Capital
  • Larry Weiss, MD, Chief Medical Officer, AOBiome
  • James White, Ph.D., Founder, Resphera Biosciences

For more information, visit: http://www.microbiomeconference.com/brochure.

This year brings several exciting additions to the conference, designed to offer attendees insights that they can implement in their own organizations. First, this year’s conference will feature two parallel tracks on the second day, closely focused on the nutrition and consumer industries within the microbiome space.

In addition, the conference will offer hands-on, intensive pre-conference workshops to help attendees understand real-world issues and give them the tools to better address how these issues impact their businesses.

For more information, please contact:

John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.
 
Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
This email address is being protected from spambots. You need JavaScript enabled to view it.